Schubert & CO Neurocrine Biosciences Inc Transaction History

Schubert & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	BUY	$106.72 - $127.06 $106 - $127	1 Added 14.29%	8 $0
Q3 2022 Oct 21, 2022	BUY	$92.03 - $107.81 $184 - $215	2 Added 40.0%	7 $1,000
Q2 2022 Aug 01, 2022	SELL	$75.79 - $100.07 $75 - $100	-1 Reduced 16.67%	5 $0
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $144 - $189	2 Added 50.0%	6 $1,000
Q4 2021 Jan 28, 2022	BUY	$79.65 - $106.22 $318 - $424	4 New	4 $0

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.